Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P H Vlasses

Showing results (11-20 of 169) with videos related to

Pageof 17
Sort By:
American Heart Journal|April 30, 1999
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Consortium perspective: what constitutes a useful economic study?C Chen, P H Vlasses
Drug Intelligence & Clinical Pharmacy|June 1, 1988
Systemic hypertension associated with cyclosporine: a reviewP J Weidle, P H Vlasses
American Heart Journal|May 1, 1981
Clinical pharmacology and therapeutic applications of the new oral angiotensin converting enzyme inhibitor, captoprilR K Ferguson, P H Vlasses
Archives of Internal Medicine|February 1, 1989
How urgent is 'urgent' hypertension?R K Ferguson, P H Vlasses
DICP : the Annals of Pharmacotherapy|February 1, 1991
Patient outcome and the future practice of pharmacyH T Hatoum, P H Vlasses
The Annals of Pharmacotherapy|January 7, 1998
Underutilization of accepted therapies: an overlooked component of pharmaceutical careP H Vlasses, C J Adarmes
JAMA|March 28, 1986
Hypertensive emergencies and urgenciesR K Ferguson, P H Vlasses
Clinical Therapeutics|May 1, 1995
Survey results from academic health center intensive care units: considerations for departments of pharmacyK A Matuszewski, P H Vlasses
Lancet (London, England)|September 8, 1979
Temporary ageusia related to captoprilP H Vlasses, R K Ferguson
The Medical Clinics of North America|March 1, 1988
Recent issues in antihypertensive drug therapyM D Cressman, P H Vlasses
Pageof 17

Showing results (11-20 of 169) with videos related to

Sort By:
Pageof 17
American Heart Journal|April 30, 1999
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Consortium perspective: what constitutes a useful economic study?C Chen, P H Vlasses
Drug Intelligence & Clinical Pharmacy|June 1, 1988
Systemic hypertension associated with cyclosporine: a reviewP J Weidle, P H Vlasses
American Heart Journal|May 1, 1981
Clinical pharmacology and therapeutic applications of the new oral angiotensin converting enzyme inhibitor, captoprilR K Ferguson, P H Vlasses
Archives of Internal Medicine|February 1, 1989
How urgent is 'urgent' hypertension?R K Ferguson, P H Vlasses
DICP : the Annals of Pharmacotherapy|February 1, 1991
Patient outcome and the future practice of pharmacyH T Hatoum, P H Vlasses
The Annals of Pharmacotherapy|January 7, 1998
Underutilization of accepted therapies: an overlooked component of pharmaceutical careP H Vlasses, C J Adarmes
JAMA|March 28, 1986
Hypertensive emergencies and urgenciesR K Ferguson, P H Vlasses
Clinical Therapeutics|May 1, 1995
Survey results from academic health center intensive care units: considerations for departments of pharmacyK A Matuszewski, P H Vlasses
Lancet (London, England)|September 8, 1979
Temporary ageusia related to captoprilP H Vlasses, R K Ferguson
The Medical Clinics of North America|March 1, 1988
Recent issues in antihypertensive drug therapyM D Cressman, P H Vlasses
Pageof 17